Spyre Therapeutics, Inc. (SYRE): R&D Expense
$171.65M
Year ended 2025-12-31
$215.80M
Trailing 12 months to 2026-06-30
+43.1%
3-year compound annual growth
+23.5%
5-year compound annual growth
+31.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $171.65M | +5.4% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $162.79M | +81.9% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $89.50M | +52.8% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $58.58M | +2.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $57.07M | -4.3% | 2024-11-18, From 2021-01-01 |
| 2020-12-31 | $59.64M | -7.7% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $64.60M | +75.9% | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $36.72M | +60.9% | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | $22.82M | +25.8% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $18.14M | +58.4% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $11.45M | +67.7% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $6.83M | n/a | 2017-03-23, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $171.65M | +5.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare SYRE, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗